Mary Kay Continues Its Commitment to Skin Science
13.1.2022 16:03:00 EET | Business Wire | Press release
Mary Kay Inc., one of the world’s innovative skincare companies, participated at two renowned European conferences in late 2021. At the 19th Aesthetic & Anti-Aging Medicine World Congress, Mary Kay Inc. submitted a scientific poster on the usage and tolerability of a highly concentrated retinol formula in Asian skin. Mary Kay Inc. also partnered with the European Society’s Dermatological Research (ESDR) in sponsoring Future Leaders in Dermatology Symposium at their 50th Annual conference. At this conference, Mary Kay Inc. shared the results of a recent clinical study that demonstrated the capability of a cosmetic formulation to alleviate symptoms associated with sensitive skin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005071/en/
Dr. Lucy Gildea, Mary Kay Chief Innovation Officer, Product and Science (Photo: Mary Kay Inc.)
The 19th Aesthetic & Anti-Aging Medicine World Congress took place from September 16-18, 2021, in Monte Carlo and was held under the High Patronage of H.S.H. Prince Albert II of Monaco. Attendees of this conference extended to several professions including dermatologists, plastic and cosmetic surgeons, anti-aging doctors, and aesthetic and general practitioners. Over 8,300 participants from 130 countries joined the conference, both in-person and virtually. The digital platform offered an immersive virtual experience that complemented the physical show allowing attendees to join the digital exhibition and watch workshops regardless of the distance or travel restrictions.
Mary Kay scientists were proud to share their latest research on retinol use and tolerability at this conference. By using a gradual retinization protocol on Asian individuals, there was an improvement in their overall skin appearance as well as a reduction in post-inflammatory hyperpigmentation - a common concern when using retinol, especially in skin of color.
“Retinol is a gold-standard skincare ingredient with many proven benefits, but the experience and tolerability of a retinol product are not the same for every person. For individuals who are concerned about potential irritation or hyperpigmentation, the results of this study offer potential solutions. I am very excited to share this research with the scientific community worldwide at AMWC’s 19th World Congress to share our innovative research with professionals in skin science and aging,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc.
“AMWC 2021 featured a multi-faceted aesthetic and anti-aging medicine program aimed at promoting high-level continued education and we were happy to have Mary Kay participate this year. We hope that we have succeeded in helping to inspire the exchange of new ideas and the sharing of ‘know-how’ in this field on a global level”, said Catherine Decuyper, EuroMediCom Founder and President. “I am grateful to our team, our global partners, the attendees, and the scientific community at large for their contributions and for the opportunity to serve them and their aesthetic and anti-aging medicine needs.”
Following the success of AMWC 2021, EuroMediCom will host AMWC 2022 from March 31 to April 2, 2022, in a hybrid format again in order to allow delegates from across the world to join them for the 20th edition of their world-leading aesthetic and anti-aging medicine congress. Registrants can choose to attend in person or watch live-streamed sessions from anywhere in the world.
The annual European Society’s Dermatological Research (ESDR) Conference is held in Europe each year every September. In 2021, due to travel restrictions and COVID-19 precautions, the annual meeting took place entirely virtually from September 22-15, 2021. ESDR supports investigative dermatology with the goal of improving the health of patients who are suffering from various skin and infectious diseases and immune disorders. In addition to presenting research, Mary Kay was also able to sponsor a Future Leaders in Dermatology symposium that kicked off the conference.
Associate Principal Scientist Geetha Kalahasti at Mary Kay Inc. shared the results of a recent clinical study that evaluated the effects of a new formulation that contained a blend of lipids identical to the skin's natural ratio, a nociceptor (TRPV-1) antagonist, and a botanical extract that reduces the expression of proinflammatory cytokines.
“At Mary Kay, we are committed to understanding skin biology and designing new products that address skin needs. One ongoing area of focus has been the relationship between sensitive skin and skin barrier function,” said Kalahasti. “Each of these materials targeted a specific biological pathway that contributes to skin redness. The findings revealed that this multi-faceted approach helps strengthen the compromised skin barrier and alleviate discomfort associated with sensitive skin.”
“On behalf of the ESDR board, we would like to thank Mary Kay for the support of the ESDR and the generous contribution to ESDR activities. One of the most important activities of our Society is to promote the presentation of new research data and ideas, and we are delighted to have Mary Kay be a part of this event,” said Leopold Eckhart, Chair, Scientific Program Committee of ESDR.
This particular symposium helps connect young researchers with renowned scientists in dermatology and encourages such collaborations – a focus that is very important to Mary Kay Inc.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
ABOUT EUROMEDICOM
EuroMediCom, created in 1999 and part of Informa Exhibitions since 2010, is dedicated to promoting Life Sciences and knowledge through educational Trainings, Conferences & Exhibitions. The main event, AMWC was created in 2003 and has since become the largest and leading medical aesthetic congress in the world. AMWC was developed with the strong belief that external aesthetic treatments and internal aging prevention could be comprehensively addressed by integrating two aspects: aesthetics strategy through dermatology and surgery procedures for external appearance and anti-aging medicine for prevention of aging and enhancement of aesthetic treatments. For more information about AMWC, click here: https://www.euromedicom.com/en/home.html
ABOUT THE EUROPEAN SOCIETY DERMATOLOGICAL RESEARCH (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and towards improving the health of patients suffering from skin and venereal disease, infectious diseases, and immune-mediated and inflammatory disorders. The ESDR facilitates exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005071/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 05:00:00 EEST | Press release
JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products and adapt flexibly to changing customer needs. EXO Travel's unique
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 02:01:00 EEST | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together, the companies will aim to develop a novel, tumour-selective therapeutic targeting a solid tumour antigen expressed across multiple difficult-to-treat cancer types. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615992992/en/ “Partnering with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to design highly optimised multispecific antibodies,”said Dr. James Field, CEO of LabGenius. “We welcome this opp
Joe Vernachio Named President of SOREL18.6.2026 01:00:00 EEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 23:30:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 23:05:00 EEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
